Targeting autophagy as a therapeutic strategy against pancreatic cancer

Keisuke Yamamoto • Dosuke Iwadate • Hiroyuki Kato • Yousuke Nakai • Keisuke Tateishi • Mitsuhiro Fujishiro

Received: 6 April 2022 / Accepted: 28 May 2022 / Published online: 21 June 2022
© The Author(s) 2022

Abstract Macroautophagy (hereafter autophagy) is a catabolic process through which cytosolic components are captured in the autophagosome and degraded in the lysosome. Autophagy plays two major roles: nutrient recycling under starvation or stress conditions and maintenance of cellular homeostasis by removing the damaged organelles or protein aggregates. In established cancer cells, autophagy-mediated nutrient recycling promotes tumor progression, whereas in normal/premalignant cells, autophagy suppresses tumor initiation by eliminating the oncogenic/harmful molecules. Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is refractory to most currently available treatment modalities, including immune checkpoint blockade and molecular-targeted therapy. One prominent feature of PDAC is its constitutively active and elevated autophagy-lysosome function, which enables PDAC to thrive in its nutrient-scarce tumor microenvironment. In addition to metabolic support, autophagy promotes PDAC progression in a metabolism-independent manner by conferring resistance to therapeutic treatment or facilitating immune evasion. Besides to cell-autonomous autophagy in cancer cells, host autophagy (autophagy in non-cancer cells) supports PDAC progression, further highlighting autophagy as a promising therapeutic target in PDAC. Based on a growing list of compelling preclinical evidence, there are numerous ongoing clinical trials targeting the autophagy-lysosome pathway in PDAC. Given the multifaceted and context-dependent roles of autophagy in both cancer cells and normal host cells, a deeper understanding of the mechanisms underlying the tumor-promoting roles of autophagy as well as of the consequences of autophagy inhibition is necessary for the development of autophagy inhibition-based therapies against PDAC.

Keywords PDAC · Autophagy · Lysosome · Host autophagy · Anti-tumor immunity

Abbreviations
TME Tumor microenvironment
PDAC Pancreatic ductal adenocarcinoma
GEMM Genetically engineered mouse model
ICB Immune checkpoint blockade
CQ Chloroquine
HCQ Hydroxychloroquine

Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a 5-year survival rate of just above 10% [1] due to the lack of early detection methods and effective treatment regimens. Despite the unprecedented success of immune checkpoint blockade (ICB) and molecular-targeted therapy in other types of cancer, the vast majority of patients with PDAC have failed to benefit from these treatment methods, apart from a minority of patients with microsatellite instability or KRAS-G12C mutation, features associated with a better response to ICB [2–4] or KRAS-G12C-specific inhibitors [5]. Major genetic alterations in PDAC include activating mutations in the
KRAS oncogene, which occur early during carcinogenesis in more than 90% of patients with PDAC, and inactivating mutations in tumor suppressor genes, such as TP53, SMAD4, and CDKN2A, which occur at later stages of disease progression in 60–70%, > 50%, and > 50% patients, respectively [6]. Unfortunately, these major mutations in PDAC remain undruggable. Therefore, it is imperative to identify novel therapeutic targets for this deadly disease based on its biological features.

One characteristic feature of PDAC tumor is its dense fibrotic stromal component, termed desmoplasia, which is composed of extracellular matrix and various stromal cells, including fibroblasts and immune cells [7]. This dense stroma hampers the efficient delivery and diffusion of oxygen and nutrients within the tumor. In addition, nutrient competition among different cell types within the tumor microenvironment (TME) makes it even harder for PDAC cells to obtain nutrients and oxygen [8]. Indeed, PDAC is one of the most hypoxic tumors [9, 10], and nutrients are scarce in surgically resected human and murine PDAC tumors as compared with normal pancreas [11, 12]. To sustain and maximize proliferation in this harsh TME, PDAC relies on enhanced intracellular scavenging via autophagy [13], extracellular scavenging via macropinocytosis [14] (Fig. 1), and nutrient acquisition from normal cells in the TME [8], all of which represent potential therapeutic targets.

Macroautophagy (hereafter autophagy) is a multistep catabolic/self-degrading process in which intracellular components are captured by the autophagosomes and degraded in the lysosomes (Fig. 2). The breakthrough discovery of autophagy-related genes by Dr. Ohsumi, who received the Nobel Prize in Medicine in 2016, has accelerated our understanding of the molecular mechanisms and roles of autophagy in both physiological and pathological contexts. Autophagy plays two key roles: (1) nutrient recycling and (2) maintenance of cellular homeostasis [15–18]. The nutrient-recycling role of autophagy is mediated mainly via bulk/non-selective autophagy, in which autophagy substrates are randomly captured and degraded. In contrast, the homeostatic role is mediated mainly via selective autophagy, in which specific targets, such as misfolded proteins, protein aggregates, or damaged organelles, are selectively removed with the help of autophagy cargo receptors that recognize and bind to their cargo to facilitate trafficking to autophagosomes [15, 17, 19]. Thus, dysfunction of selective autophagy leads to the accumulation of undesired cargo, ultimately leading to diseases, such as neurological degenerative disorders and cancer [17, 18]. Generally, bulk autophagy is induced under stress conditions, such as nutrient starvation and hypoxia, while selective autophagy is mediated by basal autophagy, which is constitutively active at the basal level regardless of nutrient status.

The role of autophagy in cancer is complicated and highly context-dependent; however, in general, the nutrient-recycling activity of autophagy promotes tumor growth by fueling tumor metabolism, whereas the homeostatic role, mainly mediated by selective autophagy, prevents tumor initiation by removing oncoproteins or potentially carcinogenic cellular constituents in normal or precancerous cells [17]. As nutrient acquisition is almost always a limiting factor for cancer-cell proliferation, autophagy-mediated nutrient recycling plays a significant role in supporting tumor growth [20, 21]. Indeed, autophagy inhibition in established tumors suppresses tumor growth in various types of cancer, especially those driven by oncogenic mutations in RAS or RAF, such as lung cancer, pancreatic cancer, and melanoma, where autophagy is constitutively activated at high levels [13, 22–27].

PDAC is a cancer with constitutively active autophagy and increased lysosomal activity/function, facilitating its
sustained growth in nutrient-scarce microenvironments. Besides this metabolic support via nutrient recycling, autophagy also promotes the progression of PDAC and other cancers via non-metabolic functions, such as treatment resistance or immune evasion. More recently, in addition to autophagy in cancer cells, host autophagy (autophagy in normal host cells) has been shown to play an important role in promoting tumor progression. In this review, we have highlighted the current knowledge on the roles and mechanisms of autophagy in cancer biology, with a special focus on PDAC.

**Autophagy suppresses the formation of precancerous lesions, but promotes their progression to cancer**

Loss of essential autophagy genes in specific tissues causes various degenerative and inflammatory diseases in mouse models, reflecting the homeostatic role of autophagy in normal tissues [17]. Similarly, autophagy deficiency is implicated in tumorigenesis in several organs, including the liver, lung, and pancreas [23, 28–32]. The link between autophagy and carcinogenesis was first described in mouse models, where heterozygous knockout of the autophagy-related gene, beclin 1 (Becn1), increased the incidence of liver and lung tumors [33, 34], which is in line with frequent allelic loss of BECN1 in human breast, ovary, and prostate cancers [35, 36]. However, follow-up studies suggested that BECN1 could be a passenger gene of the neighboring tumor suppressor gene, BRCA1 [37], raising concerns about the roles of BECN1 and autophagy as tumor suppressors.

In 2011, two groups independently showed that mosaic deletion of autophagy-related (Atg)-5 in the whole body or liver-specific deletion of Atg7 leads to spontaneous formation of adenoma, a benign tumor, in the mouse liver [28, 29], confirming the role of autophagy as a suppressor of tumorigenesis. Similarly, Atg5 ablation in KRAS-driven mouse lung cancer models accelerated benign tumor formation, but restricted its progression to adenocarcinoma [23, 30]. Likewise, studies using genetically engineered mouse models (GEMMs) of PDAC (Pdx-Cre; LSL-KrasG12D+/−;Trp53flx/fox) have shown that in the presence of oncogenic Kras, autophagy deficiency...
accelerates the formation of premalignant pancreatic intraepithelial lesions (PanINs), but blocks the progression of these benign lesions to a malignant state (PDAC) [31, 32, 38]. In the absence of oncogenic Kras, autophagy deletion alone does not lead to PanIN formation [32, 38, 39]. Notably, in a similar autochthonous KRAS-driven pancreatic cancer model with homozygous p53 deletion (Pdx1-Cre; LSL-Kras<sup>G12D</sup>/<sup>+</sup>;Trp53<sup>flox/fox</sup>), Atg5 or Atg7 knockout accelerated tumor growth [31]. These paradoxical results may be explained by the non-physiological situation in the latter model where both copies of Trp53 were simultaneously lost during embryogenesis and the pancreas developed without ever expressing p53, which may have had an immense impact on normal organogenesis and tumorogenesis [40], while in the heterozygous p53 knockout model, Trp53 was lost in a step-wise manner during tumorigenesis, which more faithfully recapitulates human tumors [32]. Together, these results suggest that autophagy plays a dual role in carcinogenesis, blocking the initiation of benign premalignant lesions and promoting their progression to malignant cancer.

One possible mechanism for enhanced carcinogenesis following autophagy ablation is the pathogenic accumulation of autophagy cargo receptor proteins, which are normally degraded via the autophagy-lysosome system, together with their cargo. As most autophagy cargo receptor proteins have multiple functions and act as signaling molecules [41], their accumulation in autophagy-deficient cells can promote tumor formation and progression via multiple mechanisms, including aberrant signal activation [42, 43]. For example, Atg5 or Atg7 deletion in mouse liver accelerates adenoma formation [28, 29]. Mechanistically, accumulation of sequestosome 1 (SQSTM1/p62) in autophagy-deficient hepatocytes leads to the activation of the nuclear factor-erythroid 2-related factor 2 (NRF2) signaling, a central pathway regulating the redox and stress response genes [44], by derepressing NRF2 from Keap1-mediated regulation, thereby promoting adenoma development [29, 45–47]. Importantly, p62 is a major component of Mallory-Denk bodies [48], which are frequently observed in chronic liver diseases and hepatocellular carcinoma [29, 47], further supporting the role of p62 accumulation in liver tumorigenesis.

In addition to bulk autophagy, selective autophagy also plays an important role in both physiological and pathological conditions, although the role of selective autophagy in PDAC development remains less studied than that of bulk autophagy. Mitophagy is a form of selective autophagy in which damaged mitochondria are removed either via a ubiquitin-dependent pathway, such as the PINK1/Parkin pathway, or a ubiquitin-independent pathway that is mediated by the mitophagy receptors, BNIP3, BNIP3L/NIX, FUNDC1, and Bcl2L13 [49]. Interestingly, oncogenic Kras upregulates Nix-mediated mitophagy and removes functional mitochondria, thereby limiting glucose flux to the mitochondria and enhancing the redox capacity to promote PanIN progression to PDAC. Nix deletion increases mitochondrial mass and reactive oxygen species (ROS) production in PanIN cells, blocking PanIN progression to PDAC [50]. In contrast, PINK1/Parkin-mediated mitophagy has been reported to inhibit pancreatic tumorigenesis by regulating the local immune response [51]. Given that both NIX and PINK1/Parkin have mitophagy-independent roles and functions, further studies are required to elucidate the exact role of mitophagy in PDAC carcinogenesis.

**PDAC relies on constitutively active autophagy for sustained tumor growth**

As mentioned previously, autophagy inhibition in established tumors suppresses tumor growth in multiple types of cancer, including PDAC, lung cancer, prostate cancer, and melanoma [13, 22–26, 52]. In 2011, human PDAC tumors and cell lines were shown to exhibit elevated levels of basal autophagy, and pharmacological or genetic inhibition of autophagy slowed the tumor growth via impaired mitochondrial metabolism and ROS accumulation [13]. This was further confirmed in a GEMM of PDAC that is driven by KRAS mutation and p53 loss of heterozygosity (Pdx1-Cre <sup>+</sup>; LSL-Kras<sup>G12D</sup>/<sup>+</sup>; Trp53<sup>flox/fox</sup>), where biallelic deletion of Atg5 decreased PDAC formation and prolonged the survival of mice [32]. Atg5-null tumors exhibit impaired proliferation, increased DNA damage, and apoptosis [32]. Importantly, pharmacological inhibition of autophagy by the lysosome inhibitor, hydroxychloroquine (HCQ), exerts tumor-suppressive effects on murine PDAC cell lines and a panel of human patient-derived xenografts, regardless of their Trp53 status [32]. Notably, a more recent study using PDAC GEMM (KRAS mutation and wild-type Trp53) (Ptf1a-Cre <sup>+</sup>; LSL-Kras<sup>G12D</sup>/?; Trp53<sup>flox/+</sup>) showed that monoallelic loss of Atg5 unexpectedly increased metastasis and shortened the survival of mice [53], although biallelic loss of Atg5 reduced PDAC formation, consistent with previous reports [31, 32]. However, it is unclear whether this enhanced aggressiveness of PDAC with monoallelic loss of Atg5 is a consequence of autophagy deficiency or autophagy-independent functions of Atg5, given that most autophagy-related proteins play multiple roles that are independent of autophagy [54].

In addition to these conditional knockout models, several new models have been developed to better understand the roles of autophagy at different stages (such as normal/premalignant lesions or full-blown tumors) in different cell types (such as malignant or normal host cells) [26, 38, 55, 56] and to model autophagy inhibitor treatment...
strategies in patients. Yang et al. developed Kras-driven PDAC GEMMs, in which autophagy can be inhibited by doxycycline-inducible expression of Atg4B<sup>C74A</sup>, a dominant negative form of the Atg4B mutant that potently inhibits autophagy [38, 57]. Once PDAC tumors were formed, autophagy was inhibited by doxycycline treatment. Upon doxycycline treatment, PDAC tumors carrying homozygous Atg4B<sup>C74A</sup> alleles showed rapid tumor regression, confirming the essential role of autophagy in established PDAC tumors. Karsli-Uzunbas et al. developed a murine non-small lung cancer model driven by Kras<sup>G12D</sup> and Trp53 deletion, where Atg7 can be acutely deleted in the whole body in a tamoxifen-inducible manner (Ubc-CreERT2<sup>+/−</sup>; Atg7<sup>flox/flox</sup>) [26]. When Atg7 was deleted after the formation of lung tumors, the tumors showed drastic regression [26]. Importantly, both models allow the inhibition of autophagy separately in cancer cells, normal host cells, or both, which revealed that blocking autophagy in normal host cells alone has a negative impact on tumor progression, shedding light on the role of host autophagy, which will be discussed later.

**Mechanism of enhanced autophagy-lysosome function in PDAC**

Autophagy is induced under various stresses, such as starvation, hypoxia, organelle damage, DNA damage, endoplasmic reticulum (ER) stress, and pathogen infection [17]. Autophagy induction in response to nutritional changes is primarily mediated by the unc-51 like autophagy activating kinase 1 (ULK1) complex, which is positively and negatively regulated by the AMP-activated protein kinase (AMPK) [58] and mechanistic target of rapamycin complex 1 (mTORC1) [59], respectively (Fig. 2). mTORC1 is a master regulator of cell growth, which, in response to nutrient availability and growth factor stimuli, promotes cellular anabolism, but inhibits catabolic pathways, including autophagy. Under nutrient-rich conditions, mTORC1 blocks autophagy induction by suppressing the ULK1 complex via the phosphorylation of ULK1/2 or ATG13 [60]. When nutrients become limiting and cellular ATP levels decrease, AMPK is activated, while mTORC1 is inhibited, leading to the activation of ULK1 complex and subsequent induction of autophagy [58]. Thus, the ULK1 complex integrates signals from the two major sensors of energy stress and nutrient status, playing a central role in autophagy induction.

In addition to this kinase-dependent regulation of acute autophagy induction, transcriptional programs are also utilized to maintain the increased activity of the autophagy-lysosome pathway. The microphthalmia/transcription factor E (MiT/TFE) family of transcription factors (MITF, TFE3, and TFEB) controls transcriptional programs for autophagy and lysosome biogenesis via the coordinated upregulation of autophagy and lysosome genes [61–63]. Under nutrient-rich conditions, MiT/TFE proteins are phosphorylated by mTORC1, leading to interactions with 14–3-3 and cytoplasmic retention. Under starved conditions, mTORC1 is inactivated and MiT/TFE factors undergo nuclear translocation, where they activate their target genes via direct binding to a consensus sequence, termed as the coordinated lysosomal expression and regulation (CLEAR) sequence [62] (Fig. 3).

Importantly, some cancers, including PDAC, exhibit elevated autophagy and lysosome biogenesis to achieve efficient nutrient recycling through degradation of lysosomal cargo, while simultaneously maintaining high mTORC1 activity to drive cellular anabolism and proliferation. Perera et al. found that PDAC cells show constitutive nuclear localization of MiT/TFE proteins, regardless of the nutrient status [64]. They showed that PDAC cells overexpress both MiT/TFE proteins and the nuclear import proteins, importin (IPO)-7 and IPO8, which facilitates the nuclear translocation of MiT/TFE factors, though the mechanism by which increased IPO7/8 levels can decouple MiT/TFE factors from mTORC1-mediated regulation in PDAC cells remains unknown. Consequently, PDAC cells exhibit constitutive activation of autophagy-lysosome transcriptional programs regardless of nutrient availability and mTORC1 activity. Importantly, depletion of MiT/TFE proteins in PDAC cells abrogates the autophagy-lysosomal function and impairs tumor growth, highlighting the critical role of this transcriptional program in the survival and growth of PDAC cells [64](Fig. 3).

Wong et al. discovered active dephosphorylation of ULK1 by protein phosphatase 2A (PP2A) as another mechanism for elevated autophagy flux in PDAC [70]. mTORC1 inhibits autophagy via the phosphorylation of ULK1 at multiple sites, including S637 and S757 [71, 72](Fig. 2). The authors found that the PP2A–B55α complex dephosphorylated S637 on ULK1 and counteracted mTORC1-mediated autophagy suppression in PDAC. They also showed that increased PP2A phosphatase activity in PDAC cells drives increased basal autophagy. Importantly, this process did not impair mTORC1 activity. Together, these studies highlight the mechanisms by which PDAC cells maintain high basal autophagy and increased lysosomal biogenesis to meet the metabolic demands, while simultaneously exploiting mTORC1 activity to maximize protein synthesis and cell proliferation.

How do PDAC cells maintain the lysosomal membrane integrity to cope with the huge influx of cargo into lysosomes? Gupta et al. used a proteomics-based approach and discovered that Myoferlin, a plasma membrane repair factor, is enriched in the lysosomal membranes of PDAC cells, maintaining their integrity and function [65].
Importantly, Myoferlin is upregulated in human PDAC, which is associated with poor patient survival, and Myoferlin ablation abrogates tumor growth in murine PDAC models, highlighting the crucial role of the autophagy-lysosomal pathway in PDAC progression [65].

**Host autophagy supports tumor metabolism**

Although initial studies mainly focused on the role of autophagy in cancer cells, recent studies have demonstrated that host autophagy (autophagy in normal host cells) also contributes to tumor progression. Karsli–Uzunbas et al. used Kras$^{G12D}$- and Trp53$^{-/-}$-driven murine lung cancer models and showed that the conditional knockout of Atg7 in the whole body (in host and cancer cells) leads to the substantial regression of established tumors, which, surprisingly, was even greater than Atg7-knockout in cancer cells alone, suggesting that both host autophagy and tumor-specific autophagy support tumor growth [26]. Similar results were obtained in different models, including GEMM of non-small lung cancer, melanoma, PDAC [38, 55, 56], and RasG12V-driven tumors in *Drosophila melanogaster* [66], where autophagy-proficient cancer cells were transplanted into autophagy-proficient or autophagy-deficient animals. In these studies, tumor growth was impaired when cells were transplanted into autophagy-deficient hosts, confirming the tumor-promoting role of host autophagy.

How does host autophagy support tumor growth? Sousa et al. showed that pancreatic stellate cells (PSCs), a major source of cancer-associated fibroblasts (CAFs) in PDAC tumor stroma [67], secrete alanine in an autophagy-dependent manner [68]. This PSC-derived alanine is taken up by PDAC cells to fuel the tricarboxylic acid cycle and for the de novo synthesis of non-essential amino acids and free fatty acids, allowing PDAC cells to use glucose and glutamine, two key nutrients that are scarce in the PDAC TME [11, 12], for other biosynthesis pathways, such as nucleic acid biogenesis [69] and production of NADPH to maintain redox balance [70]. Thus, autophagy-dependent alanine secretion from PSCs plays a pivotal role in supporting the unique metabolism of PDAC cells (Fig. 4). A follow-up study revealed the detailed mechanism of this alanine crosstalk, where PSCs use SLC1A4 to secrete alanine, and PDAC cells upregulate SLC38A2 to take up alanine [71]. Notably, SLC38A2 ablation causes a metabolic crisis in PDAC cells, but not in normal cells, leading to substantial tumor regression, highlighting the crucial role of PSC-derived alanine in supporting the unique metabolic rewiring in PDAC cells [71]. Similarly, host autophagy supports tumor growth by sustaining circulating arginine levels, especially in cancer types that lack arginine synthase expression and require exogenous arginine for survival [55]. Depletion of Atg5 or Atg7 in host cells leads to arginase 1 secretion, an arginine-degrading enzyme, from the liver into the circulation, which degrades and lowers serum arginine levels, eventually impairing the growth of arginine auxotrophic tumors [55].

How do cancer cells induce autophagy in healthy host cells? Katheder et al. used an RAS-driven tumor model in *D. melanogaster* and discovered that tumor cells trigger autophagy in neighboring cells and distant organs, which fuels tumor growth and metastasis by providing amino acids [66]. The authors further identified tumor-cell-derived ROS as key mediators regulating host autophagy, although factors other than ROS may also be involved in autophagy induction in host cells, particularly in distant organs.
In addition to alanine, CAFs also secrete other metabolites, such as lipids, which support biomass production in PDAC cells [72], and pyrimidine, a deoxycytidine that blunts the efficacy of the nucleotide analog, gemcitabine [73, 74]. CAFs also secrete various cytokines and chemokines, including C-X-C motif chemokine ligand (CXCL)-12, interleukin (IL)-6, leukemia inhibitory factor (LIF), and Netrin-G1, to promote PDAC progression [75–77]. Notably, the activation of PSCs into tumor-promoting CAFs requires the upregulation of autophagy [68, 78] as well as other stimuli, such as vitamin D receptor (VDR) signaling [79]. Taken together, these data suggest that targeting autophagy in host cells, including PSCs/CAFs, represents an attractive therapeutic strategy for PDAC and other cancers.

Host autophagy promotes tumor immune tolerance

To date, many studies have demonstrated that host autophagy supports tumor metabolism by providing essential nutrients. Recent studies have also shed light on the role of host autophagy as a negative regulator of anti-tumor immunity, where the inhibition of autophagy in host cells enhances anti-tumor immune responses and suppresses tumor growth.

Autophagy in the liver

Poillet-Perez et al. used murine melanomas that carry a high tumor mutational burden and demonstrated that the loss of autophagy in normal host cells, especially in the liver, promotes T cell infiltration into tumors, limiting tumor growth in a T cell-dependent manner [56]. Mechanistically, the authors showed that host autophagy suppresses anti-tumor T cell responses by enhancing the regulatory T cell (Treg) functions and suppressing interferon-g signaling, although the exact mediators remain to be elucidated.

Autophagy in T cells

DeVorkin et al. reported that loss of autophagy in CD8+ T cells enhances their tumor-cell-killing effect and impairs tumor growth [80]. Mechanistically, autophagy inhibition shifts T cells to a more glycolytic state and reduces the production of S-adenosylmethionine (SAM), an important methyl-donor, leading to global changes in epigenetic modifications, including the loss of H3K27me3 and gain of H3K4me3 marks. These epigenetic alterations transcriptionally reprogram CD8+ T cells to an effector memory state, enabling the efficient killing of cancer cells.

Autophagy-related pathways in myeloid cells

Other autophagy-related pathways in host cells have also been shown to regulate the anti-tumor immune responses. LC3-associated phagocytosis (LAP) is a form of phagocytosis used by macrophages to clear pathogens or dead cells and regulate their immune responses [81]. LAP utilizes many core components of the autophagy pathway, including VPS34, BECN1, ATG3, ATG7, and ATG12. Cunha et al. showed that the impairment of LAP, but not autophagy, in tumor-associated macrophages transforms them into a tumor suppressive M1 subtype, which promotes anti-tumor T cell responses and impairs tumor growth [82]. Similarly, Chen et al. showed that the lysosomal inhibitor chloroquine (CQ) impairs tumor growth by reprogramming macrophages from the tumor-promoting M2 subtype to the tumor-suppressive M1 subtype and enhancing the anti-tumor T cell response. Together, these studies revealed that autophagy and lysosome-related activity in host cells promote tumor immune tolerance, representing attractive therapeutic targets to enhance the anti-tumor immunity.
Autophagy facilitates immune evasion across cancer types

PDAC is one of the tumor types most resistant to ICB. Apart from rare cases with microsatellite instability-high (MSI-High) or mismatch repair deficiency (dMMR) [2–4], the vast majority of patients with PDAC have failed to benefit from ICB [83–86]. This resistance of PDAC to ICB has been ascribed to multiple factors, including immune suppressive TME, limited number of CD8\(^{+}\) T cells infiltrating the tumor, or low tumor mutational burden [87], features that have been verified in GEMMs of PDAC [88]. However, more recent evidence has revealed that human PDAC tumors have a varying number of CD8\(^{+}\) T cells with considerable intratumoral heterogeneity and sometimes harbor antigens that can stimulate potent T cell immunity [89–92], raising the possibility that there may be other undiscovered factors mediating immunotherapy resistance.

Major histocompatibility complex class I (MHC-I) is a key component of the acquired immune system, in which cells present endogenous peptides to CD8\(^{+}\) T cells. If virus-infected cells or cancer cells present peptides derived from non-self proteins, such as viral components or mutated proteins, CD8\(^{+}\) T cells recognize these non-self peptides with their T-cell receptors (TCRs) and eliminate these cells. Unsurprisingly, MHC-I expression or other antigen presentation machinery, which is indispensable for CD8\(^{+}\) T cell-mediated tumor-cell killing, is frequently dysregulated or lost in various cancer types, resulting in resistance to ICB [93–96]. In both human and mouse PDAC tumors, MHC-I expression is downregulated, which is particularly evident in liver metastasis [97, 98]. However, unlike other types of cancer, mutations in MHC-I are rare in PDAC [99]. A recent study led by a joint team of the Kimmelman and Perera labs demonstrated that MHC-I is actively degraded via autophagy in PDAC, thereby reducing cell surface MHC-I levels and facilitating immune evasion [100, 101]. The team also identified NBR1 as an autophagy cargo receptor that enables the selective targeting and degradation of MHC-I molecules in autophagosomes and lysosomes. Importantly, genetic and pharmacological inhibition of autophagy/lysosome activity restores cell surface MHC-I expression, increases T-cell infiltration into tumor, and sensitizes PDAC to ICB in murine models [100, 101] (Fig. 5). In line with this, a recent clinical trial using HCQ and gemcitabine plus nab-paclitaxel (GnP), a standard-of-care chemotherapy for PDAC [102], as neoadjuvant chemotherapy (NCT01978184), showed that the addition of HCQ increased the number of tumor-infiltrating CD8\(^{+}\) T cells [103, 104]. Additionally, a recent study identified tumor-cell-derived progranulin (PGRN) as a driver of autophagy-dependent MHC-I degradation and subsequent immune evasion [105]. The authors used surgically resected human PDAC tumors and showed that increased PGRN expression in PDAC cells is associated with lower MHC-I expression and fewer CD8\(^{+}\) T cell infiltration as well as shorter patient survival. Importantly, inhibition of PGRN by a neutralizing antibody blocked this autophagy-mediated MHC-I degradation, restoring MHC-I expression in PDAC cells, and enhancing anti-tumor T cell responses in the murine PDAC model [105]. Together, these studies support the role of autophagy as a negative regulator of MHC-I-mediated antigen presentation in PDAC, highlighting that autophagy inhibition is a promising strategy for sensitizing PDAC to ICB.

Accumulating evidence supports the role of autophagy as a negative regulator of anti-tumor immunity in various types of cancer. Notably, multiple studies using unbiased genome-wide CRISPR knockout screens have identified autophagy as a key cancer-cell intrinsic mechanism that drives immune evasion across cancer types [106–108] (Table 1). The major mechanisms of autophagy-mediated immune evasion include impaired antigen presentation [100, 101, 105, 109], downregulation of T cell-attracting chemokines, such as CXCL9 and CXCL10 [110–113], and resistance to interferon-\(\gamma\) and TNF-\(\alpha\), key inflammatory mediators that are released from cytotoxic CD8\(^{+}\) T cells [106–108]. In addition to autophagy in cancer cells, host autophagy and other autophagy-related pathways in host cells contribute to tumor immune evasion [56, 80, 82, 114]. Based on these compelling preclinical results, several ongoing clinical trials are combining autophagy inhibition and ICB to treat PDAC (Table 2).

Autophagy as a driver of therapeutic resistance

Autophagy has been implicated in resistance to treatment [115–117]. For example, the mitogen-activated protein kinase (MAPK) pathway, a downstream pathway of KRAS, plays a central role in the initiation and progression of cancers driven by RAS or RAF mutations, including PDAC, colorectal cancer, lung cancer, and melanoma [118]. Therapeutic approaches targeting major components of the RAS–MAPK pathway, such as RAF, MEK, and ERK, have been hampered by the inevitable emergence of acquired resistance [119]. One such mechanism is increased autophagy flux, which was initially shown in a study where PDAC cells that survived oncogenic KRAS ablation exhibited elevated autophagy [120]. Consistently, several groups have found that the RAS–MAPK pathway inhibition increases autophagy flux in multiple cancer types, including PDAC, and that combined inhibition of the RAS–MAPK pathway and autophagy exerts synergistic anti-tumor effects [121–123]. Notably, the combination of the MEK inhibitor, trametinib, and HCQ resulted in drastic...
tumor shrinkage in a patient with metastatic PDAC [122]. More recently, Jiang et al. reported that dual inhibition of MEK and autophagy, but not either treatment alone, activates the STING/type I interferon pathway in PDAC cells, which reprograms tumor-associated macrophages into a tumor-suppressive M1-like subtype [124]. Importantly, the addition of an agonistic antibody to CD40, a costimulatory molecule that licenses and activates antigen-presenting cells upon ligand engagement [125], further augments this autophagy/MEK inhibition-mediated immune response, eliciting robust T-cell responses in triple therapy [124]. Based on these promising preclinical data, multiple clinical trials are underway to test the efficacy of the combined treatment with HCQ and MEK/ERK inhibitors (Table 2).

**Clinical trials targeting autophagy in PDAC**

Currently, lysosomal inhibitors, CQ and HCQ, which have long been used as antimalarial drugs, are the only clinically available agents to block autophagy. Both compounds have been used in several clinical trials to target various cancers, including PDAC [116]. Although HCQ showed only minimal activity when used as monotherapy [126], HCQ plus GnP significantly improved the response rates compared with GnP alone (21% vs. 38%, \( p = 0.047 \)) [127], showed an improved pathological response, and increased immune cell infiltration [103, 104](NCT01978184), further confirming the role of autophagy as a key resistance mechanism against therapeutic treatment. Based on these findings, multiple clinical trials are ongoing to test the efficacy of combining autophagy/lysosome inhibitors (mainly HCQ) with conventional chemotherapy, targeted therapy, and ICB (Table 2).

**Acquired resistance to autophagy inhibition**

Autophagy inhibition is a promising therapeutic option; hence, the emergence of acquired resistance to autophagy inhibition is an obstacle that must be overcome for effective treatment. Recent studies have identified NRF2 upregulation as a major mechanism by which cancer cells circumvent autophagy inhibition [128, 129]. Towers et al. found that cancer cells that have adapted to autophagy deficiency upregulate NRF2 signaling, a master regulator of cellular stress responses [44], thereby compensating for the impaired ubiquitin proteasome system function and ER stress caused by autophagy deficiency [128]. Su et al. showed that the inhibition of autophagy in PDAC cells upregulates macropinocytosis to enhance extracellular nutrient scavenging, which is mediated by NRF2-driven transcriptional upregulation of macropinocytosis-related genes [129]. In both studies, compensatory NRF2 signaling following autophagy inhibition was induced by the accumulation of the autophagy cargo receptor protein, p62, which blocks Keap1-mediated degradation of NRF2 [45, 46, 130], thereby derepressing NRF2 activity [128, 129]. Importantly, these studies demonstrated that combining proteasome inhibition [128] or macropinocytosis inhibition [129] is effective in overcoming resistance to autophagy inhibition in PDAC.

**Future perspectives**

Despite compelling preclinical evidence showing the efficacy of autophagy inhibition as a therapeutic strategy against PDAC, clinical trials using the lysosomal inhibitor, CQ/HCQ, have shown only minimal to modest impact on patient prognosis (Table 2). Given the unfavorable
| Cancer types | Study methods | Comments | Refs |
|--------------|---------------|----------|------|
| Pancreatic cancer | Short hairpin RNA (shRNA)-mediated knock down of autophagy-related (ATG) genes; Overexpression of Atg4B<sup>C74A</sup>; Murine syngeneic tumor transplantation models | MHC-I is degraded via NBR-I-mediated selective autophagy in PDAC cells, promoting their immune evasion. Autophagy-inhibition restores cell surface MHC-I expression and sensitizes PDAC to immune checkpoint blockade (ICB) | [100, 101] |
| Pancreatic cancer | Blocking antibody against progranulin (PGRN); Genetically engineered mouse model (GEMM) of PDAC; Murine syngeneic tumor transplantation models | Tumor-derived PGRN drives autophagy-dependent MHC-I degradation in PDAC. Increased PGRN expression in PDAC cells is associated with low MHC-I expression, decreased CD8<sup>+</sup> T cell infiltration, and decreased patient survival. PGRN blockade restores MHC-I expression in PDAC cells, improving anti-tumor T cell responses | [105] |
| Pancreatic cancer | Murine syngeneic tumor transplantation model; Cobimetinib (MEK inhibitor), mefloquine (MFQ, lysosome inhibitor) | Dual inhibition of MEK and autophagy in PDAC cells activates the STING/type I interferon (IFN) pathway, which polarizes tumor-associated macrophages into tumor-suppressive M1-like subtype. Addition of agonistic antibody to CD40 further augments this autophagy/MEK inhibition-mediated immune response, eliciting robust T cell responses | [124] |
| Melanoma; Breast cancer; Renal cell carcinoma; Colorectal cancer | Genome-wide CRISPR knockout screen; Murine syngeneic tumor transplantation models | Autophagy pathway is identified as a top-ranked mediator of immune evasion by cancer cells. Mechanistically, autophagy in cancer cells confers resistance to IFN-g and TNF-a that are released from cytotoxic T lymphocytes | [106–108] |
| Melanoma; Colorectal cancer | Vps34 inhibitor, shRNA to Vps34; Murine syngeneic tumor transplantation models | Vps34 inhibition/knockdown increases cancer cell secretion of CXCL5 and CXCL10, which recruit natural killer, CD4<sup>+</sup> T, and CD8<sup>+</sup> T cells into tumors, leading to tumor regression and improved response to ICB | [111] |
| Melanoma; Colorectal cancer | CRISPR-mediated knockout of Atg7; Murine syngeneic tumor transplantation models | Upon syngeneic transplantation, Atg7-knockout mouse cancer cells stimulated enhanced anti-tumor immune response, which was mediated by CD8<sup>+</sup> T cells. This enhanced immune response likely depends on the immunogenicity of the cancer cells | [136] |
| Breast cancer | CRISPR-mediated knockout of Atg5 and Atg7; Murine syngeneic tumor transplantation models | Upon radiation, autophagy-deficient cancer cells accumulate mitochondrial DNA in the cytosol, which stimulates the cGAS-STING pathway and induces type I IFN secretion, resulting in improved response to ICB and tumor regression in non-irradiated and irradiated lesions (Abscopal effect) | [112] |
| Non small cell lung cancer (NSCLC) | MRT68921 (ULK1 inhibitor) or CQ; overexpression of Atg4B<sup>C74A</sup>; Murine syngeneic tumor transplantation models | Inactivating mutations in serine/threonine kinase 11 (STK11/LKB1) are found in 20% of NSCLC cases and associated with poor response to ICB. LKB1 deficiency increases mutational burden and suppresses antigen processing and presentation, which are associated with compromised immunoproteasome activity and elevated autophagy flux. Inhibition of autophagy by an ULK1 inhibitor restores antigen presentation and sensitizes LKB1-mutant NSCLC to programmed death 1 (PD1) blockade therapy | [109] |
| Prostate cancer | PIKfyve inhibitor ESK981; Murine syngeneic tumor transplantation models | A multi kinase inhibitor, ESK981, showed potent anti-tumor effects on castration-resistant prostate cancer (CRPC) tumor in a CD8<sup>+</sup> T cell-dependent manner. Mechanistically, ESK981 targets the lipid kinase, PIKfyve, and blocks autophagy flux in CRPC cells, which results in increased release of T-cell chemoattractants, CXCL10 and CCL2, thereby enhancing T cell infiltration into tumors and potentiating ICB response | [113] |
pharmacokinetics of these drugs in vivo [131], more potent inhibitors are required to improve the patient outcome. Additionally, to accelerate the development of novel inhibitors and identify patients likely to benefit from autophagy inhibitors, it is crucial to develop reliable biomarkers, preferably less invasive ones that enable repeated measurements, to facilitate the monitoring of autophagy activity in human patients [132]. Another concern in the use of CQ/HCQ to block autophagy is the fact that CQ/HCQ is not specific to autophagy: CQ/HCQ inhibits lysosomal acidification and impairs all lysosome-related pathways, including endocytosis, macropinocytosis, LAP [81], and LC3-associated endocytosis (LANDO), a process recently shown to be involved in β-amyloid clearance and neurodegeneration prevention [133]. However, given the tumor-promoting roles of macropinocytosis in PDAC cells [129] and LAP in host cells [82], inhibiting all lysosome-related pathways using CQ/HCQ may be more efficacious than autophagy-specific inhibition in PDAC treatment. More potent and specific autophagy inhibitors are required, both as clinical drug candidates and research tools.

Another unanswered question regarding the use of autophagy inhibition as a therapeutic strategy is whether autophagy should be inhibited only in cancer cells or systematically in the whole body, although there is no autophagy-lysosome inhibitor that can specifically target only

| Disease                                   | Interventions                              | Results                                                                 | Study phase | Refs                      |
|-------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------|-------------|---------------------------|
| Previously treated, metastatic            | HCQ                                        | 0% response                                                             | II          | NCT01273805               |
| Borderline resectable                     | Gem + HCQ (neoadjuvant)                    | CA19-9 decrease in 61% cases; R0 resection in 77% cases; Prolonged OS in patients with significant autophagy inhibition in peripheral blood cells (34.83 vs 10.83 months, p < 0.05) | I/II        | NCT01128296               |
| Metastatic or unresectable                | Gem + CQ                                   | Median PFS, 4 months; Median OS, 7.6 months                             | I           | NCT01777477               |
| Previously untreated, metastatic or advanced | GnP ± HCQ                                 | Improved RR in GnP with HCQ than in GnP without HCQ (38.2 vs 21.1%); no difference in OS and PFS | II          | NCT01506973               |
| Resectable or borderline resectable       | GnP ± HCQ (neoadjuvant)                    | Addition of HCQ to GnP improved histopathologic RR (p = 0.00016) and tumor infiltrating CD8 + T cells. Intratumoral αβ T cell receptor clonality was associated with CA 19–9 response and prolonged OS | II          | NCT01978184               |
| Previously untreated, Metastatic          | GnP + HCQ + Ipilimumab (anti-CTLA4 antibody) | Ongoing                                                                | I           | NCT04787991               |
| Gastrointestinal cancer (pancreatic and colorectal cancer) | Cobimetinib (MEK inhibitor) + Atezolizumab (anti-PDL1 antibody) + HCQ | Ongoing                                                                | I/II        | NCT04214418               |
| Advanced                                  | Trametinib (MEK inhibitor) + HCQ           | Ongoing                                                                | I           | NCT03825289               |
| Metastatic                                | Binimetinib (MEK inhibitor) + HCQ          | Ongoing                                                                | I           | NCT04132505               |
| Advanced                                  | Ulixertinib (ERK inhibitor) + HCQ          | Ongoing                                                                | I           | NCT04145297               |
| Metastatic                                | LY3214996 ± HCQ (ERK inhibitor)           | Ongoing                                                                | II          | NCT04386057               |
| Advanced pancreatic cancer                | mPOLFIRINOX + HCQ + Chlorophenesin Carbamate | Ongoing                                                                | I           | NCT05083780               |
| Advanced or metastatic                    | Gem + nabpaclitaxel ± Paricalcitol (Vitamin D receptor agonist) plus HCQ (GnP ± PH) | Ongoing                                                                | II          | NCT04524702               |

*Gem* gemcitabine, *GnP* gemcitabine + nabpaclitaxel, *HCQ* hydroxychloroquine, *OS* overall survival, *PFS* progression-free survival, *RR* response rate, *R0* resection, complete tumor removal with negative resection margins.
cancer cells. Given the tumor-promoting roles of host autophagy and tumor-cell intrinsic autophagy, blocking autophagy in both cancer and host cells may be more efficacious. However, considering the multifaceted functions of autophagy in normal physiology, it is important to determine the effect of autophagy inhibition on normal cells in the body. In particular, when inhibiting autophagy to enhance the anti-tumor immune response, the effects of autophagy inhibition on respective immune cells and anti-tumor immune response have to be carefully determined, as previous studies have shown both favorable [134] and unfavorable [135] effects of autophagy inhibition on different types of immune cells. To this end, a detailed analysis of the surgically resected tumors that received preoperative treatment regimens involving autophagy inhibition may be of great help to expand our knowledge [131].

Acknowledgements K.Y. was supported by the Yasuda Medical Foundation, Tokyo Society of Medical Sciences, MSD Life Science Foundation, Astellas Foundation for Research on Metabolic Disorders, Uehara Memorial Foundation, Princess Takamatsu Cancer Research Fund, Life Science Foundation of Japan, and JSPS KAKENHI (Grant numbers 21K20828, 22H02898, and 22H03053).

Declarations

Conflict of interest All authors declare that they have no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
2. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
3. Humphris JL, Patch AM, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152(68–74): e2.
4. Luchini C, Bibeau F, Lichtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232–43.
5. Hong DS, Fakhri MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17.
6. Biaikin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.
7. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505.
8. Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27:863–75.
9. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol. Phys. 2000;48:919–22.
10. Hollinshead KER, Parker SJ, Eapen VV, et al. Respiratory supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer. Cell Rep. 2020;33:108231.
11. Kamphorst JJ, Nofal M, Commissio C, et al. Human pancreatic tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75:544–53.
12. Sullivan MR, Danai LV, Lewis CA, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife. 2019;8.
13. Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717–29.
14. Commissio C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633–7.
15. Komatsu M, Waguri S, Ueno T, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005;169:425–34.
16. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280–93.
17. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728–41.
18. Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383:1564–76.
19. Kirkin V, McEwan DG, Novak I, et al. A role for ubiquitin in selective autophagy. Mol Cell. 2009;34:259–69.
20. Guo JY, Teng X, Laddha SV, et al. Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. Genes Dev. 2016;30:1704–17.
21. Poillet-Perez L, Sarry JE, Joffre C. Autophagy is a major metabolic regulator involved in cancer therapy resistance. Cell Rep. 2021;36:109528.
22. Guo JY, Chen HY, Mathew R, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011;25:460–70.
23. Guo JY, Karsli-Uzunbas G, Mathew R, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytes and maintains lipid homeostasis. Genes Dev. 2013;27:1447–61.
24. Lock R, Roy S, Kenific CM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011;22:165–78.
25. Perera RM, Bardeesy N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 2015;5:1247–61.
26. Karsli-Uzunbas G, Guo JY, Price S, et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 2014;4:914–27.
27. Ma XH, Piao S, Wang D, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res. 2011;17:3478–89.
28. Takamura A, Komatsu M, Harai T, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25:795–800.
48. Denk H, Stumptner C, Fuchsbichler A, et al. Are the Mallory
47. Umemura A, He F, Taniguchi K, et al. p62, Upregulated during
46. Komatsu M, Kurokawa H, Waguri S, et al. The selective
44. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf het-
42. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
41. Moscat J, Karin M, Diaz-Meco MT. p62 in cancer: signaling
40. Amaravadi R, Debnath J. Mouse models address key concerns
39. Antonucci L, Fagman JB, Kim JY, et al. Basal autophagy
38. Yang A, Herter-Sprie G, Zhang H, et al. Autophagy sustains
37. Laddha SV, Ganesan S, Chan CS, et al. Mutational landscape of
35. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic
34. Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene
33. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by
31. Rosenfeldt MT, O’Prey J, Morton JP, et al. p53 status deter-
30. Rao S, Tortola L, Perlot T, et al. A dual role for autophagy in a
29. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of
28. Yang A, Rajeshkumar NV, Wang X, et al. Autophagy is critical
27. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
26. Antonucci L, Fagman JB, Kim JY, et al. Basal autophagy
25. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by
24. Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene
23. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by
22. Yang A, Herter-Sprie G, Zhang H, et al. Autophagy sustains
21. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
20. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of
19. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic
18. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by
17. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
16. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by
15. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic
14. Yang A, Herter-Sprie G, Zhang H, et al. Autophagy sustains
13. Antonucci L, Fagman JB, Kim JY, et al. Basal autophagy
12. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
11. Moscat J, Karin M, Diaz-Meco MT. p62 in cancer: signaling
10. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor
9. Wei H, Wang C, Croce CM, et al. p62/SQSTM1 synergizes with autophagy for tumor growth in vivo. Genes Dev. 2014;28:1204–16.
8. Antonucci L, Fagman JB, Kim JY, et al. Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. Proc Natl Acad Sci U S A. 2015;112:E1666–74.
7. Amaravadi R, Debnath J. Mouse models address key concerns regarding autophagy inhibition in cancer therapy. Cancer Discov. 2014;4:873–5.
6. Moscat J, Karin M, Diaz-Meco MT. p62 in cancer: signaling adaptor beyond autophagy. Cell. 2016;167:606–9.
5. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008;13:343–54.
4. Wei H, Wang C, Croce CM, et al. p62/SQSTM1 synergizes with autophagy for tumor growth in vivo. Genes Dev. 2014;28:1204–16.
3. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313–22.
2. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–84.
1. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–84.
71. Parker SI, Amendola CR, Hollinshead KER, et al. Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer. Cancer Discov. 2020;10:1018–37.
72. Auciello FR, Bulusu V, Oon C, et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 2019;9:617–27.
73. Shukla SK, Purohit V, Mehla K, et al. MUC1 and HIF-1alpha signaling crosstalk initiates anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(71–87): e7.
74. Dalin S, Sullivan MR, Lau AN, et al. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 2019;79:5725–33.
75. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68:918–26.
76. Shi Y, Gao W, Lyle NK, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019;569:131–5.
77. Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, et al. Nctrin GI promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression. Cancer Discov. 2021;11:446–79.
78. Endo S, Nakata K, Ohuchida K, et al. Autophagy is required for activation of pancreatic stellate cells, associated with pancreatic cancer progression and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;152(1492–1506): e24.
79. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80–93.
80. DeVorkin L, Pavey N, Carleton G, et al. Autophagy regulation of metabolism is required for CD8(+ T cell anti-tumor immunity. Cell Rep. 2019;27(502–513): e5.
81. Martinez J, Almendinger J, Oberst A, et al. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A. 2011;108:17396–401.
82. Cunha LD, Yang M, Carter R, et al. LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance. Cell. 2018;175(429–441): e16.
83. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic ductal adenocarcinoma. J Immunother. 2013;36:382–9.
84. De Vorkin L, Pavey N, Carleton G, et al. Autophagy regulation of metabolism is required for CD8(+ T cell anti-tumor immunity. Cell Rep. 2019;27(502–513): e5.
85. Martinez J, Almendinger J, Oberst A, et al. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A. 2011;108:17396–401.
86. Cheung PF, Yang J, Fang R, et al. Progralanin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nat Commun. 2022;13:156.
87. Lawson KA, Sousa CM, Zhang X, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586:120–6.
88. Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156:2056–72.
89. Bailey P, Chang DK, Forget MA, et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016;6:35848.
90. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
91. Balachandran VP, Lukszka M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551:512–6.
92. Poschke I, Faryna M, Bergmann F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5: e1240859.
93. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61.
94. McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific immune evasion of lung cancer evolution. Cell. 2017;171(1259–1271): e11.
95. Gettinger S, Choi J, Hastings K, et al. Impaired HLA Class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420–35.
96. Grasso CS, Giannakis M, Wells DK, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730–49.
97. Ryschich E, Notzel T, Hinz U, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005;11:498–504.
98. Pommier A, Anaparthi N, Memos N, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018. https://doi.org/10.1126/science.aao4908.
99. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
100. Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100–5.
101. Yamamoto K, Venida A, Perera RM, et al. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Autophagy. 2020; https://doi.org/10.1080/15548627.2020.1769973.
102. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
103. Zeh H, Bahary N, Boone BA, et al. A randomized Phase II preoperative study of autophagy inhibition with high-dose oxycloxorouquine and gemcitabine/nab-paclitaxel in pancreatic cancer patients. Clin Cancer Res. 2020. https://doi.org/10.1158/0007-4084.CCR-19-4042.
104. Murthy PW, Daniel, Sharma N S, Singhla D A, et al. Intratumoral T cell clonality and survival in a randomized Phase II study of preoperative autophagy inhibition in combination with gemcitabine and nab-paclitaxel treatment in patients with resectable pancreatic cancer. J Clin Oncol. 2021; https://doi.org/10.1200/JCO.2021.39.15_suppl.e16001.
105. Cheung PF, Yang J, Fang R, et al. Progralanin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nat Commun. 2022;13:156.
106. Lawson KA, Sousa CM, Zhang X, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586:120–6.
107. Young TM, Reyes C, Pasnikowski E, et al. Autophagy protects tumors from T cell-mediated cytotoxicity via inhibition of TNApahs-induced apoptosis. Sci immunol. 2020. https://doi.org/10.1126/sciimmunol.abb9561.
108. Dubrot J, Lane-Reticker SK, Kessler EA, et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector...
system reveal immune dependencies in renal cell carcinoma. Immunity. 2021. https://doi.org/10.1016/j.immuni.2021.01.001.

109. Deng J, Thennavan A, Dolgalev I, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nature Cancer. 2021;2:503–14.

110. Wei H, Wei S, Gan B, et al. Suppression of autophagy by FIP200 depletion inhibits mammary tumorigenesis. Genes Dev. 2011;25:1510–27.

111. Noman MZ, Parpal S, Van Moer K, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-L1/PD-L1 immunotherapy. Science advances. 2020;6:eaaax7881.

112. Yamazaki T, Kirchmair A, Sato A, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020;21:1160–71.

113. Qiao Y, Choi JE, Tien JC, et al. Autophagy inhibition by targeting pikfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature cancer. 2021;2:978–93.

114. Chen D, Xie J, Fiskerud R, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9:873.

115. Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016;30:1913–30.

116. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9:1167–81.

117. Takahashi FS, Vangestel C, Tanc M, et al. ATG4B inhibitor UAMC-2526 potentiates a, Chemotherapeutic effect of gemcitabine in a panc02 mouse model of pancreatic ductal adeno-carcinoma. Front Oncol. 2021;11:750259.

118. Collisson EA, Trejo CL, Silva JM, et al. A central role for RAF–MEK–ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012;2:685–93.

119. Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072–81.

120. Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628–32.

121. Bryant KL, Stalnecker CA, Zeitouni D, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25:628–40.

122. Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF–MEK–ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019;25:620–7.

123. Lee CS, Lee LC, Yuan TL, et al. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proc Natl Acad Sci U S A. 2019;116:4508–17.

124. Jiang H, Courau T, Borison J, et al. Activating immune recognition in pancreatic ductal adenocarcinoma via autophagy inhibition, MEK blockade, and CD40 agonism. Gastroenterology. 2022;162(590–603): e14.

125. Beatty GL, Chiorian EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–6.

126. Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19:637–8.

127. Karasic TB, O’Hara MH, Loaiza-Bonilla A, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a Phase 2 randomized clinical trial. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2019.0684.

128. Towers CG, Fitzwalter BE, Regan D, et al. Cancer cells upregulate NRF2 signaling to adapt to autophagy inhibition. Dev Cell. 2019;50(690–703): e6.

129. Su H, Yang F, Fu R, et al. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell. 2021. https://doi.org/10.1016/j.ccell.2021.02.016.

130. Lau A, Wang XJ, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275–85.

131. Munster T, Gibbs JP, Shen D, et al. Hydroxylchloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.

132. Mizushima N, Murphy LO. Autophagy assays for biological discovery and therapeutic development. Trends Biochem Sci. 2020;45:1080–93.

133. Heckmann BL, Teubner BJW, Tummers B, et al. LC3-associated endocytosis facilitates beta-amyloid clearance and mitigates neurodegeneration in murine alzheimer’s disease. Cell. 2019;178(536–551): e14.

134. DeVorkin L, Hattersley M, Kim P, et al. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Molecular cancer research: MCR. 2017;15:250–8.

135. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573–7.

136. Arensman MD, Yang XS, Zhong W, et al. Anti-tumor immunity influences cancer cell reliance upon ATG7. Oncoimmunology. 2020;9:1800162.

137. Boone BA, Bahary N, Zureikat AH, et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:4402–10.

138. Samaras P, Tusup M, Nguyen-Kim TDL, et al. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2017;80:1005–12.

139. Egan DF, Chun MG, Vamos M, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell. 2014;59:285–97.

140. Petherick KJ, Conway OJ, Mpamhanga C, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015;290:11376–83.

141. Martin KR, Celano SL, Solitto AR, et al. A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress. iScience. 2018;8:74–84.

142. Bago R, Malik N, Munson MJ, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J. 2014;463:413–27.

143. Dowdle WE, Nyfeler B, Nagel J, et al. Selective VPS34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2011;7:868–71.

144. Lau A, Wang XJ, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275–85.
146. Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223–34.
147. Fu Y, Hong L, Xu J, et al. Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. Autophagy. 2019;15:295–311.
148. Chu J, Fu Y, Xu J, et al. ATG4B inhibitor FMK-9a induces autophagy independent on its enzyme inhibition. Arch Biochem Biophys. 2018;644:29–36.
149. Akin D, Wang SK, Hahibzadegah-Tari P, et al. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy. 2014;10:2021–35.
150. McAfee Q, Zhang Z, Samanta A, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A. 2012;109:8253–8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.